Aurobindo Pharma's Q4 net down 14%

Aurobindo Pharma Ltd's net profit declined 14 per cent at Rs 107 crore in the fourth quarter ended March 31, 2012, compared with Rs 125 crore in the corresponding quarter of previous year. For the full year, the Hyderabad-based company posted a net loss of Rs 123.5 crore. During the last financial year, it earned Rs 563 crore net profit. The revenue had, however, gone up by 10.7 per cent at Rs 4,567 crore (Rs 4,125 crore). The profitability during FY12 was impacted mainly due to sharp decline in dossier income by Rs 196 crore and loss of revenues of about Rs 201 crore due to the impact of the US Food and Drug Administration's alert on Unit VI in Hyderabad, the company said. “We have concluded a challenging year highlighted by full impact of the USFDA alert on our Unit 6 Cephalosporin manufacturing facility, high cost of materials, inflation and notional loss on restatement of foreign currency borrowings,” said the Aurobindo Pharma CEO, Mr N. Govindarajan. Aurobindo's scrip declined 3.85 per cent on the BSE on Friday to end at Rs 104.95.